Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers created a hydrogel that reduces oxidative stress and releases a pro-angiogenic drug in response to enzyme activity, which accelerated healing and improved tissue regeneration in chronic diabetic wounds during in vivo experiments.

In this study, researchers highlight the role of androgens like dihydrotestosterone in the pathophysiology of acne, pointing to the enzyme 5a-reductase type 1 as potentially more active in individuals with acne, which may contribute to hormonal influences in the condition's development.

In this study, Diane was reported to effectively treat acne, seborrhoea, androgenic alopecia, and mild hirsutism in hirsute women, with its effectiveness influenced by the severity and duration of the condition.

This study found that DHEA significantly inhibited growth and induced autophagy in a mouse melanoma cell line, but showed only muffled inhibition and induced apoptosis in a human melanoma cell line.

This review found no evidence that DHEA improves quality of life or decreases menopausal symptoms in peri- and postmenopausal women, but it may slightly enhance sexual function compared to placebo.

Dupilumab can cause psoriasis in some patients.

The authors concluded that dutasteride is effective and generally safe for managing benign prostatic hyperplasia and may reduce prostate cancer risk.

This review discusses the consensus reached by international experts on guidelines for prescribing and monitoring low-dose oral minoxidil for hair loss, and reports no new clinical results.

Dutasteride reduces DHT more effectively than finasteride.

This study reviewed literature on using the dermapem technique for treating female androgenetic alopecia and found that it effectively controls and stabilizes hair loss by enhancing nutrient supply and absorption in the scalp, with the technique considered safe.

This study developed a topical dutasteride-loaded Insitu-emulgel for treating androgenetic alopecia, finding it effectively controls drug release, enhances skin penetration, and may improve patient compliance compared to traditional topical treatments, though further clinical research is underway.

Dupilumab may cause hair loss in some patients with severe atopic dermatitis.

This review examines experimental and clinical evidence on PDRN, a drug derived from salmon DNA that acts via the adenosine A2A receptor and shows promise for tissue repair and treatment of diabetic foot ulcers in regenerative medicine.

In this study, dexpanthenol exhibited antiepileptic and antidepressant-like effects in mice without impacting their motor coordination.

This study observed that dermatologists and physicians who frequently treat male pattern hair loss have practices and attitudes that may create a favorable care environment compared to less experienced physicians.

This study reported the development of two highly sensitive ELISA assays to detect banned substances finasteride and dutasteride in human urine, offering better sensitivity than existing HPLC/MS/MS methods.

This study found that DHA, a derivative of artemisinin, shows potential as a cosmetic ingredient due to its anti-aging, anti-hair loss, antibacterial, whitening, and anti-glycation activities.

This pilot clinical study introduces DEC cells as a novel therapy for Duchenne muscular dystrophy, confirming safety and efficacy in seven patients up to 24 months post-treatment.

This report suggests that for prostate cancer patients with cardiovascular disease, prescribing the GnRH antagonist degarelix may reduce cardiac events compared to using GnRH agonists, although prescribing should consider potential cardiac risks, particularly in patients with pre-existing conditions or older age.

This study found that capped mesoporous silica nanoparticles conjugated with antibodies selectively released a dye when exposed to finasteride, with low detection limits and stable performance even after storage.

This study found that a 400-mg dose of oral testosterone with dutasteride increases serum testosterone levels for 8–10 hours in hypogonadal men, with the nanomilled formulation unaffected by food, suggesting a practical twice-daily therapy option.

This study describes the development of microneedle array patches for finasteride that released the drug over 7 to 14 days in vitro, suggesting a potential alternative to oral treatments for long-term management of benign prostatic hyperplasia and androgenic alopecia.

This case report suggests that frequent application of diphenylcyclopropenone 2% solution to the scalp for alopecia areata may lead to scalp angioedema.

This study found that DVd therapy is at least as effective as VAD/VAd for treating multiple myeloma and causes fewer side effects and reduced hospital visits.

This study found that combining MSM with MAP significantly enhanced hair growth in mice, comparable to or better than minoxidil, due to increased intradermal retention of MAP.

In this randomized clinical trial, the authors reported that after 12 weeks, 5% dapsone gel was more effective than 1% clindamycin phosphate gel in treating mild to moderate acne vulgaris, showing efficacy in 78.2% of patients compared to 52.7% with clindamycin.

This study found that dihydrotestosterone induces hair loss in male C57BL/6 mice, and this effect can be partially reversed by the androgen receptor antagonist bicalutamide.

This study found that combining minoxidil 0.1% and dutasteride 0.01% applied topically after microneedling was significantly more effective than using dutasteride alone with microneedling in improving female pattern hair loss in 40 female patients.

In this study, low concentrations of DMSO were found to decrease androgen receptor expression and inhibit the migration of prostate cancer cells, suggesting potential as an anticancer therapy.

This study found that Soluplus and L-ascorbyl 2,6-dipalmitate nanoparticles may improve minoxidil's skin permeability through stable hydrophobic interactions, enhancing its potential for targeted skin application.